RxDoctor Payments Data

Cortney Langerholc

Family · Johnstown, PANPI 1386260396

Payments from drug & device makers

$5,591in general payments, 2019–2025

Across 346 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$535
  • Lilly USA, LLC$485
  • Pfizer$378
  • Novo Nordisk$363
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$330
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,52599%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,591 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$32,250
Medicare patients
143
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$22,770
JardianceEmpagliflozin11$15,434
XareltoRivaroxaban19$13,903
MounjaroTirzepatide11$11,381
EliquisApixaban12$9,822
Pantoprazole Sodium67$889
Atorvastatin Calcium52$877
SynthroidLevothyroxine Sodium20$868
Potassium Chloride29$847
Duloxetine Hcl28$846
Lamotrigine33$763
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide14$651
Levothyroxine Sodium48$568
Metoprolol Succinate33$482
Lorazepam69$421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$363$22,77022 claims
Boehringer IngelheimJardiance$117$15,43411 claims
Johnson & JohnsonXarelto$27$13,90319 claims
Lilly USA, LLCMounjaro$485$11,38111 claims
PfizerEliquis$378$9,82212 claims
AbbVieSynthroid$1,148$86820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →